EE48 Cost-Effectiveness of Alternative Diagnostic Testing Pathways with Whole Exome Sequencing (WES) in a Rare Disease Patient Population: The Canadian Care-for-Rare SOLVE (SOLVE) Multi-Centre Observational Cohort
Abstract
Authors
K Degeling L Grazziotin Lago RZ Hayeems KM Boycott FP Bernier R Mendoza-Londono TA Seeger D Marshall